Dengue: An update on treatment options

Future Microbiology

Volumn 10, Issue 12, 2015, Pages 2017-2031

  Chan, Candice Yy ^a,b   Ooi, Eng Eong ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

antiviral drug; dengue; flavivirus; therapeutic monoclonal antibodies

Indexed keywords

166347; ADENOSINE TRIPHOSPHATASE INHIBITOR; ANTIVIRUS AGENT; ARDP 006; BALAPIRAVIR; CASTANOSPERMINE 6 BUTYRATE; CHLOROQUINE; COMPOUND 23I; COMPOUND 7N; CROMOGLYCATE DISODIUM; HELICASE INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; KETOTIFEN; LYCORINE; MEVINOLIN; MONOCLONAL ANTIBODY; MONTELUKAST; NITD 008; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOSIDE ANALOG; POLYCLONAL ANTIBODY; PROTEINASE INHIBITOR; RNA DIRECTED RNA POLYMERASE INHIBITOR; SDM 25N; TYROTHRICIN; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT ENHANCEMENT; ANTIBODY TITER; ANTIVIRAL THERAPY; BLEEDING; CASE MANAGEMENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; CONFORMATIONAL TRANSITION; CONTROLLED CLINICAL TRIAL (TOPIC); DENGUE; DISEASE DURATION; ENDOPLASMIC RETICULUM STRESS; FLUID RESUSCITATION; FLUID THERAPY; GOLD STANDARD; HEALTH CARE QUALITY; HEART INDEX; HUMAN; INCUBATION TIME; INNATE IMMUNITY; MOLECULAR WEIGHT; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEROTYPE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; UNFOLDED PROTEIN RESPONSE; VIRUS LOAD; VIRUS REPLICATION; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; PROCEDURES; TRENDS;

CLINICAL TRIALS AS TOPIC; DENGUE; DRUG DISCOVERY; FLUID THERAPY; HUMANS;

EID: 84948388825     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.15.105     Document Type: Review

References (114)

1. Bhatt S, Gething PW, Brady OJ et al. The global distribution and burden of dengue. Nature 496(7446), 504-507 (2013).
2. Guzman MG, Halstead SB, Artsob H et al. Evaluating diagnostics. Nature 8(12), S7-S16 (2010).
3. CDC. http://www.cdc.gov/dengue/epidemiology
4. Gubler DJ. Dengue, urbanization and globalization: the unholy trinity of the 21st century. Trop. Med. Health 39(Supplement), S3-S11 (2011).
5. Gubler DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol. 10(2), 100-103 (2002).
6. Mackenzie JS, Williams DT. The zoonotic flaviviruses of southern, south-eastern and eastern Asia, and Australasia: the potential for emergent viruses. Zoonoses Public Health 56(6-7), 338-356 (2009).
7. World Health Organization. Dengue, Dengue Haemorrhagic Fever and Dengue Shock Syndrome in the Context of the Integrated Management of Childhood Illness. WHO, Geneva, Switzerland, 1-40 (2005).
8. Beatty ME, Beutels P, Meltzer MI et al. Health economics of dengue: a systematic literature review and expert panel's assessment. Am. J. Trop. Med. Hyg. 84(3), 473-488 (2011).
9. Rothman AL. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nature 11(8), 532-543 (2011).
10. Mustafa MS, Rasotgi V, Jain S, Gupta V. Discovery of fifth serotype of dengue virus (DENV-5): a new public health dilemma in dengue control. Med. J. Armed Forces India 71(1), 67-70 (2015).
11. Guzman MG, Harris E. Seminar: dengue. Lancet 385(9966), 453-465 (2015).
12. Noisakran S, Onlamoon N, Songprakhon P, Hsiao H-M, Chokephaibulkit K, Perng GC. Cells in dengue virus infection in vivo. Adv. Virol. 2010(5), 164878 (2010).
13. Schmid MA, Diamond MS, Harris E. Dendritic cells in dengue virus infection: targets of virus replication and mediators of immunity. Front. Immunol. 5, 647 (2014).
14. Prestwood TR, May MM, Plummer EM, Morar MM, Yauch LE, Shresta S. Trafficking and replication patterns reveal splenic macrophages as major targets of dengue virus in mice. J. Virol. 86(22), 12138-12147 (2012).
15. World Health Organization. DENGUE: Guidelines for Diagnosis, Treatment, Prevention and Control (New Edition). WHO, Geneva, Switzerland, 1-160 (2009).
16. Green AM, Beatty PR, Hadjilaou A, Harris E. Innate immunity to dengue virus infection and subversion of antiviral responses. J. Mol. Biol. 426(6), 1148-1160 (2014).
17. Morrison J, Aguirre S, Fernandez-Sesma A. Innate immunity evasion by dengue virus. Viruses 4(12), 397-413 (2012).
18. Rothman AL, Hirsch MJ, EL B. Pathogenesis of dengue virus infection. UpToDate, Waltham, MA, USA.
19. Gagnon SJ, Ennis FA, Rothman AL. Bystander target cell lysis and cytokine production by dengue virus-specific human CD4(+) cytotoxic T-lymphocyte clones. J. Virol. 73(5), 3623-3629 (1999).
20. de Alwis R, Beltramello M, Messer WB et al. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl. Trop. Dis. 5(6), e1188 (2011).
21. Dejnirattisai W, Jumnainsong A, Onsirisakul N et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 328(5979), 745-748 (2010).
22. Beltramello M, Williams KL, Simmons CP et al. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8(3), 271-283 (2010).
23. Cedillo-Barrón L, Garciá-Cordero J, Bustos-Arriaga J, León-Juárez M, Gutiérrez-Castañeda B. Antibody response to dengue virus. Microbes Infect. 16 (9), 711-720 (2014).
24. Wahala WMPB, de Silva AM. The human antibody response to dengue virus infection. Viruses 3(12), 2374-2395 (2011).
25. Pierson TC, Diamond MS. Vaccine development as a means to control dengue virus pathogenesis: do we know enough Ann. Rev. Virol. 1(1), 375-398 (2014).
26. Chan KR, Zhang SL-X, Tan HC et al. Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection. Proc. Natl Acad. Sci. USA 108(30), 12479-12484 (2011).
27. Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibodydependent enhancement of infection. Arch. Virol. 158(7), 1445-1459 (2013).
28. Thomas L, Verlaeten O, Cabié A et al. Influence of the dengue serotype, previous dengue infection, and plasma viral load on clinical presentation and outcome during a dengue-2 and dengue-4 co-epidemic. Am. J. Trop. Med. Hyg. 78(6), 990-998 (2008).
29. Low JG, Ooi E, Tolfvenstam T et al. Early dengue infection and outcome study (EDEN)-study design and preliminary findings. Ann. Acad. Med. Singap. 35(11), 783 (2006).
30. Libraty DH, Endy TP, Houng H-SH et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J. Infect. Dis. 185(9), 1213-1221 (2002).
31. Malavige GN, Huang L-C, Salimi M, Gomes L, Jayaratne SD, Ogg GS. Cellular and cytokine correlates of severe dengue infection. PLoS ONE 7(11), e50387 (2012).
32. Rathakrishnan A, Wang SM, Hu Y et al. Cytokine expression profile of dengue patients at different phases of illness. PLoS ONE 7(12), e52215 (2012).
33. Fink J, Gu F, Ling L et al. Host gene expression profiling of dengue virus infection in cell lines and patients. PLoS Negl. Trop. Dis. 1(2), e86 (2007).
34. Tolfvenstam T, Lindblom A, Schreiber MJ et al. Characterization of early host responses in adults with dengue disease. BMC Infect. Dis. 11(1), 209 (2011).
35. Sun P, Garciá J, Comach G et al. Sequential waves of gene expression in patients with clinically defined dengue illnesses reveal subtle disease phases and predict disease severity. PLoS Negl. Trop. Dis. 7(7), e2298 (2013).
36. Devignot S, Sapet C, Duong V et al. Genome-wide expression profiling deciphers host responses altered during dengue shock syndrome and reveals the role of innate immunity in severe dengue. PLoS ONE 5(7), e11671 (2010).
37. Ubol S, Masrinoul P, Chaijaruwanich J, Kalayanarooj S, Charoensirisuthikul T, Kasisith J. Differences in global gene expression in peripheral blood mononuclear cells indicate a significant role of the innate responses in progression of dengue fever but not dengue hemorrhagic fever. J. Infect. Dis. 197(10), 1459-1467 (2008).
38. Yacoub S, Wertheim H, Simmons CP, Screaton G, Wills B. Cardiovascular manifestations of the emerging dengue pandemic. Nat. Rev. Cardiol. 11(6), 335-345 (2014).
39. Wang W-K, Chao D-Y, Kao C-L et al. High levels of plasma dengue viral load during defervescence in patients with dengue hemorrhagic fever: implications for pathogenesis. Virology 305(2), 330-338 (2003).
40. Guilarde AO, Turchi MD, Siqueira JB Jr. et al. Dengue and dengue hemorrhagic fever among adults: clinical outcomes related to viremia, serotypes, and antibody response. J. Infect. Dis. 197(6), 817-824 (2008).
41. Wang W-K, Chen H-L, Yang C-F et al. Slower rates of clearance of viral load and virus-containing immune complexes in patients with dengue hemorrhagic fever. Clin. Infect. Dis. 43(8), 1023-1030 (2006).
42. Vaughn DW, Green S, Kalayanarooj S et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 181(1), 2-9 (2000).
43. Murgue B, Roche C, Chungue E, Deparis X. Prospective study of the duration and magnitude of viraemia in children hospitalised during the 1996-1997 dengue-2 outbreak in French Polynesia. J. Med. Virol. 60(4), 432-438 (2000).
44. Ngo NT, Cao XT, Kneen R et al. Acute management of dengue shock syndrome: a randomized double-blind comparison of 4 intravenous fluid regimens in the first hour. Clin. Infect. Dis. 32(2), 204-213 (2001).
45. Wagner BK, D'Amelio LF. Pharmacologic and clinical considerations in selecting crystalloid, colloidal, and oxygen-carrying resuscitation fluids, Part 1. Clin. Pharm. 12(5), 335-346 (1993).
46. Wills BA, Nguyen MD, Ha TL et al. Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N. Engl. J. Med. 353(9), 877-889 (2005).
47. Dung NM, Day NP, Tam DT et al. Fluid replacement in dengue shock syndrome: a randomized, double-blind comparison of four intravenous-fluid regimens. Clin. Infect. Dis. 29(4), 787-794 (1999).
48. Kalayanarooj S. Choice of colloidal solutions in dengue hemorrhagic fever patients. J. Med. Assoc. Thai. 91(Suppl. 3), S97-S103 (2008).
49. Dellinger RP, Levy MM, Rhodes A et al. Surviving sepsis campaign. Crit. Care Med. 41(2), 580-637 (2013).
50. Lum LCS, Goh AYT, Keong Chan PW, El-Amin A-LM, Lam SK. Risk factors for hemorrhage in severe dengue infections. J. Pediatr. 140(5), 629-631 (2002).
51. Leo Y-S, Thein TL, Fisher DA et al. Confirmed adult dengue deaths in Singapore: 5 year multi-center retrospective study. BMC Infect. Dis. 11, 123 (2011).
52. Lye DC, Lee VJ, Sun Y, Leo Y-S. Lack of efficacy of prophylactic platelet transfusion for severe thrombocytopenia in adults with acute uncomplicated dengue infection. Clin. Infect. Dis. 48(9), 1262-1265 (2009).
53. Krishnamurti C, Kalayanarooj S, Cutting MA et al. Mechanisms of hemorrhage in dengue without circulatory collapse. Am. J. Trop. Med. Hyg. 65(6), 840-847 (2001).
54. Sellahewa KH, Samaraweera N, Thusita KPGD, Fernando JLIN. Is fresh frozen plasma effective for thrombocytopenia in adults with dengue fever A prospective randomised double blind controlled study. Ceylon Med. J. 53(2), 36-40 (2008).
55. Assir MZK, Kamran U, Ahmad HI et al. Effectiveness of platelet transfusion in dengue fever: a randomized controlled trial. Transfus. Med. Hemother. 40(5), 362-368 (2013).
56. Hahn BH, McMahon MA, Wilkinson A et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 64(6), 797-808 (2012).
57. Pongpanich B, Bhanchet P, Phanichyakarn P, Valyasevi A. Studies on dengue hemorrhagic fever. clinical study: an evaluation of steroids as a treatment. J. Med. Assoc. Thai. 56(1), 6-14 (1973).
58. Min M, U T, Aye M, Shwe TN, Swe T. Hydrocortisone in the management of dengue shock syndrome. Southeast Asian J. Trop. Med. Public Health 6(4), 573-579 (1975).
59. Sumarmo Talogo W, Asrin A, Isnuhandojo B, Sahudi A. Failure of hydrocortisone to affect outcome in dengue shock syndrome. Pediatrics 69(1), 45-49 (1982).
60. Tassniyom S, Vasanawathana S, Chirawatkul A, Rojanasuphot S. Failure of high-dose methylprednisolone in established dengue shock syndrome: a placebo-controlled, double-blind study. Pediatrics 92(1), 111-115 (1993).
61. Kularatne SAM, Walathara C, Mahindawansa SI et al. Efficacy of low dose dexamethasone in severe thrombocytopenia caused by dengue fever: a placebo controlled study. Postgrad. Med. J. 85(1008), 525-529 (2009).
62. Tam DTH, Ngoc TV, Tien NTH et al. Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial. Clin. Infect. Dis. 55(9), 1216-1224 (2012).
63. Shashidhara KC, Sudharshan Murthy KA, Basavana Gowdappa H, Bhograj A. Effect of high dose of steroid on platelet count in acute stage of dengue fever with thrombocytopenia. J. Clin. Diagn. Res. 7(7), 1397-1400 (2013).
64. Panpanich R, Sornchai P, Kanjanaratanakorn K. Corticosteroids for treating dengue shock syndrome. Cochrane Database Syst. Rev. 3, CD003488 (2006).
65. Samuelsson A. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291(5503), 484-486 (2001).
66. Dimaano EM, Saito M, Honda S et al. Lack of efficacy of high-dose intravenous immunoglobulin treatment of severe thrombocytopenia in patients with secondary dengue virus infection. Am. J. Trop. Med. Hyg. 77(6), 1135-1138 (2007).
67. St John AL, Rathore APS, Raghavan B, Ng M-L, Abraham SN. Contributions of mast cells and vasoactive products, leukotrienes and chymase, to dengue virus-induced vascular leakage. eLife 2, e00481 (2013).
68. St John AL, Rathore APS, Yap H et al. Immune surveillance by mast cells during dengue infection promotes natural killer (NK) and NKT-cell recruitment and viral clearance. Proc. Natl Acad. Sci. USA 108(22), 9190-9195 (2011).
69. Apte-Sengupta S, Sirohi D, Kuhn RJ. Coupling of replication and assembly in flaviviruses. Curr. Opin. Virol. 9, 134-142 (2014).
70. Tricou V, Minh NN, Van TP et al. A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl. Trop. Dis. 4(8), e785 (2010).
71. Modis Y, Ogata S, Clements D, Harrison SC. Structure of the dengue virus envelope protein after membrane fusion. Nature 427(6972), 313-319 (2004).
72. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases Lancet Infect. Dis. 3(11), 722-727 (2003).
73. Borges MC, Castro LA, Fonseca BALD. Chloroquine use improves dengue-related symptoms. Mem. Inst. Oswaldo Cruz. 108(5), 596-599 (2013).
74. Courageot MP, Frenkiel MP, Santos Dos CD, Deubel V, Desprès P. Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum. J. Virol. 74(1), 564-572 (2000).
75. Rathore APS, Paradkar PN, Watanabe S et al. Antiviral research. Antiviral Res. 92(3), 453-460 (2011).
76. Durantel D. Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection. Curr. Opin. Investig. Drugs 10(8), 860-870 (2009).
77. Low JG, Sung C, Wijaya L et al. Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a Phase 1b, randomised, double-blind, placebo-controlled, proof-ofconcept trial. Lancet Infect. Dis. 14(8), 706-715 (2014).
78. Martinez-Gutierrez M, Correa-Londonõ LA, Castellanos JE, Gallego-Gómez JC, Osorio JE. Lovastatin delays infection and increases survival rates in AG129 mice infected with dengue virus serotype 2. PLoS ONE 9(2), e87412 (2014).
79. Rachoin J-S, Cerceo E, Dellinger RP. A new role for statins in sepsis. Crit. Care. 17(1), 105 (2012).
80. Whitehorn J, Van VCN, Truong NT et al. Lovastatin for adult patients with dengue: protocol for a randomised controlled trial. Trials 13(1), 203 (2012).
81. Whitehorn J, Yacoub S, Anders KL et al. Dengue therapeutics, chemoprophylaxis, and allied tools: state of the art and future directions. PLoS Negl. Trop. Dis. 8(8), e3025 (2014).
82. Lim SP, Wang Q-Y, Noble CG et al. Ten years of dengue drug discovery: progress and prospects. Antiviral Res. 100(2), 500-519 (2013).
83. Chan KR, Ong EZ, Ooi EE. Therapeutic antibodies as a treatment option for dengue fever. Expert Rev. Anti-Infect. Ther. 11(11), 1147-1157 (2013).
84. Zheng A, Yuan F, Kleinfelter LM, Kielian M. A toggle switch controls the low pH-triggered rearrangement and maturation of the dengue virus envelope proteins. Nat. Commun. 5, 3877 (2014).
85. La Guardia De C, Lleonart R. Progress in the identification of dengue virus entry/fusion inhibitors. BioMed. Res. Int. 2014, 825039 (2014).
86. Nguyen NM, Tran CNB, Phung LK et al. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J. Infect. Dis. 207(9), 1442-1450 (2013).
87. Nelson DR, Zeuzem S, Andreone P et al. Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. Ann. Hepatol. 11(1), 15-31 (2012).
88. Dong H, Zhang B, Shi P-Y. Flavivirus methyltransferase: a novel antiviral target. Antiviral Res. 80(1), 1-10 (2008).
89. Lim SP, Sonntag LS, Noble C et al. Small molecule inhibitors that selectively block dengue virus methyltransferase. J. Biol. Chem. 286(8), 6233-6240 (2011).
90. Yin Z, Chen Y-L, Schul W et al. An adenosine nucleoside inhibitor of dengue virus. Proc. Natl Acad. Sci. USA 106(48), 20435-20439 (2009).
91. Gu B, Liu C, Lin-Goerke J et al. The RNA helicase and nucleotide triphosphatase activities of the bovine viral diarrhea virus NS3 protein are essential for viral replication. J. Virol. 74(4), 1794-1800 (2000).
92. Byrd CM, Grosenbach DW, Berhanu A et al. Novel benzoxazole inhibitor of dengue virus replication that targets the NS3 helicase. Antimicrob. Agents Chemother. 57(4), 1902-1912 (2013).
93. Phong WY, Moreland NJ, Lim SP, Wen D, Paradkar PN, Vasudevan SG. Dengue protease activity: the structural integrity and interaction of NS2B with NS3 protease and its potential as a drug target. Biosci. Rep. 31(5), 399-409 (2011).
94. Zou J, Xie X, Lee LT et al. Dimerization of flavivirus NS4B protein. J. Virol. 88(6), 3379-3391 (2014).
95. Green AM, Beatty PR, Hadjilaou A, Harris E. Innate immunity to dengue virus infection and subversion of antiviral responses. J. Mol. Biol. 426(6), 1148-1160 (2014).
96. Xie X, Wang QY, Xu HY et al. Inhibition of dengue virus by targeting viral NS4B protein. J. Virol. 85(21), 11183-11195 (2011).
97. Miller S, Sparacio S, Bartenschlager R. Subcellular localization and membrane topology of the dengue virus type 2 non-structural protein 4B. J. Biol. Chem. 281(13), 8854-8863 (2006).
98. Zou G, Puig-Basagoiti F, Zhang B et al. A single-amino acid substitution in West Nile virus 2K peptide between NS4A and NS4B confers resistance to lycorine, a flavivirus inhibitor. Virology 384(1), 242-252 (2009).
99. van Cleef KWR, Overheul GJ, Thomassen MC et al. Identification of a new dengue virus inhibitor that targets the viral NS4B protein and restricts genomic RNA replication. Antiviral Res. 99(2), 165-171 (2013).
100. Krause I, Wu R, Sherer Y, Patanik M, Peter JB, Shoenfeld Y. In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations-a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfus. Med. 12(2), 133-139 (2002).
101. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin. Rev. Allergy Immunol. 29(3), 173-184 (2005).
102. Lok S-M, Kostyuchenko V, Nybakken GE et al. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat. Struct. Mol. Biol. 15(3), 312-317 (2008).
103. Tharakaraman K, Robinson LN, Hatas A et al. Redesign of a cross-reactive antibody to dengue virus with broad-spectrum activity and increased in vivo potency. Proc. Natl Acad. Sci. USA 110(17), E1555-E1564 (2013).
104. Robinson LN, Tharakaraman K, Rowley KJ et al. Structure-guided design of an anti-dengue antibody directed to a nonimmunodominant epitope. Cell 162(3), 493-504 (2015).
105. de Alwis R, Smith SA, Olivarez NP et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc. Natl Acad. Sci. USA 109(19), 7439-7444 (2012).
106. Teoh EP, Kukkaro P, Teo EW et al. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci. Transl. Med. 4(139), 13983-13983 (2012).
107. Fibriansah G, Tan JL, Smith SA et al. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat. Commun. 6, 1-10 (2015).
108. Fibriansah G, Ibarra KD, Ng T-S et al. Dengue virus. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science 349(6243), 88-91 (2015).
109. Dejnirattisai W, Wongwiwat W, Supasa S et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat. Immunol. 16(2), 170-177 (2015).
110. Lyons AG. The human dengue challenge experience at the Walter Reed Army Institute of Research. J. Infect. Dis. 209(Suppl. 2), S49-S55 (2014).
111. Mammen MP, Lyons A, Innis BL et al. Evaluation of dengue virus strains for human challenge studies. Vaccine 32(13), 1488-1494 (2014).
112. Sabchareon A, Wallace D, Sirivichayakul C et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled Phase 2b trial. Lancet 380(9853), 1559-1567 (2012).
113. Thomas SJ. Preventing dengue-is the possibility now a reality N. Engl. J. Med. 372(2), 172-173 (2015).
114. Villar L, Dayan GH, Arredondo-Garciá JL et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N. Engl. J. Med. 372(2), 113-123 (2015).